Based on these results, we hypothesized that GPX3 mediates the AMPK/mTOR signaling pathway by regulating the level of ROS in tumor cells and triggering an imbalance of oxidative stress in the body, which subsequently has an impact on the level of pyrimidine metabolism and 5-Fu resistance in patients with STAD. This evidence concerns the gene GPX3 and neoplasm.